At least in the real world biotechs, and what their stock is worth is based on products marketed, along with stage of products still in CT, and number of competing products.
If we step out of Kenny dream world for a moment, total health expenditures for PC cancer is $2.4B. Probably more than 1/2 is Dr, Hospital, diagnostic, surgical, radiation, and supportive care costs. Let's assume 1/2 of the $2.4B, even though it's probably higher, is devoted to non-chemo, and other treatments. That would leave $1.2B for actual treatments, with 90% of that going for first line drugs. Including maintenance therapy after remission. One is now down to $210M, to be divided among the 2nd line treatments. Congratulations... with the O/S at 1.2B+, your shares would be worth about 0.04. Which is an improvement on the current asset worth of the shares or 0.00.